- Conditions
- Cold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS)
- Interventions
- Sutimlimab
- Drug
- Lead sponsor
- RECORDATI GROUP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 429 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • San Luis Obispo, California • Santa Maria, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced May 22, 2026, 5:47 AM EDT